Compare SKWD & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKWD | RXRX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | 611 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2022 | 2021 |
| Metric | SKWD | RXRX |
|---|---|---|
| Price | $60.59 | $3.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $70.73 | $7.32 |
| AVG Volume (30 Days) | 309.5K | ★ 27.0M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | 14.79 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $1,416,541,000.00 | $74,681,000.00 |
| Revenue This Year | $39.34 | N/A |
| Revenue Next Year | $6.68 | $26.91 |
| P/E Ratio | $28.14 | ★ N/A |
| Revenue Growth | 23.16 | ★ 26.92 |
| 52 Week Low | $40.60 | $2.77 |
| 52 Week High | $65.69 | $6.70 |
| Indicator | SKWD | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 46.54 |
| Support Level | $55.18 | $2.90 |
| Resistance Level | $63.49 | $3.88 |
| Average True Range (ATR) | 1.41 | 0.44 |
| MACD | 0.61 | -0.09 |
| Stochastic Oscillator | 92.94 | 10.57 |
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.